Healthcare
Theravance Biopharma, Inc.(TBPH)
Live Price
Offline$16.64
+0.91% today
1Y Change
+56.54%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $860.00M
- Revenue Growth
- +66.9%
- EPS Growth
- +282.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theravance Biopharma, Inc. (TBPH) is a Healthcare stock with a market cap of $860.00M and listed on NASDAQ. The stock last traded around $16.64 and up 56.5% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +66.9%, EPS growth of +282.6%, a dividend yield of 0.0%. What stands out right now is revenue +66.9%, EPS +282.6%, free cash flow +2109.8% with operating margin -12.3% and ROIC -2.4%. Valuation already assumes a fairly strong business story at P/E 8.1 and price/sales 8.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TBPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+66.9% vs +7.6% peer median
Operating Margin
Below sector median
-12.3% vs +19.4% peer median
P/E
Below sector median
8.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +66.9% and EPS at +282.6%, with operating margin around -12.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -1.8% | -1.0% | +0.8% |
2026 Mar 19, 2026 | -86.4% | +2.3% | +8.4% | +23.0% |
2025 Nov 10, 2025 | +233.3% | +22.7% | +19.6% | +18.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TBPH
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TBPH Max Drawdown
-34.57%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TBPH and SPY.
Company Overview
Theravance Biopharma, Inc.
NASDAQ Global Market
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
- Leadership
- Rick E. Winningham
- IPO Date
- May 16, 2014
- Employees
- 97
- Street Address
- Ugland House
- Mailing
- George Town, KY1-1104
- Region
- George Town, KY
- Reporting Currency
- USD
- Investor Line
- 6508086000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 8.1
- EV/EBITDA
- 933.8
- Price/Sales
- 8.0
- Price/Book
- 2.9
Growth
- Revenue
- +66.9%
- EPS
- +282.6%
- Free Cash Flow
- +2109.8%
Profitability
- Gross Margin
- 94.9%
- Operating Margin
- -12.3%
- Net Margin
- 98.5%
- ROE
- 46.0%
- ROIC
- -2.4%
Balance Sheet
- Debt/Equity
- 0.25
- Current Ratio
- 10.93
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.